Holen Sie sich die Stockscreener-App
1.42
3.65%
0.05
Handel nachbörslich:
1.43
0.01
+0.70%
Coherus Oncology Inc Aktie (CHRS) Neueste Nachrichten
Coherus BioSciences stock reacts to BlackRock stake and latest oncology focus - AD HOC NEWS
CHRS Q2 2026 Earnings: Narrower-than-Expected Loss Drives 2.59% Share GainPost-Earnings Reaction - vinanet.vn
Coherus to Participate in Upcoming Investor Conferences - Yahoo Finance
Coherus Oncology files $50M at-the-market sales agreement with Leerink Partners - TradingView
Coherus (CHRS) Quarter in Focus: The Bottom-Line Figure Beats Its Comparison at the Close; Closing Reaction: Shares Finish 4.23% Down for the Current SessionEarnings Growth Analysis - vinanet.vn
Coherus: 'Hold' On Several Tagmokitug 2026 Catalysts And Casdozokitug HCC Drug Development - Seeking Alpha
Coherus (CHRS) Q2 2026 Results: Reported EPS Tops Expectations in Latest Trading; Market Reaction: Shares Finish 16.52% UpEarnings Power Value - vinanet.vn
Form 8K Coherus BioSciences Inc For: 17 August By Investing.com - Investing.com India
CHRS Looks 10.6% Overvalued on GF Value™ - GuruFocus
Coherus Oncology Secures $55M Term Loan, Extends Debt Maturity to 2031 - Minichart
Coherus Declares Special Dividend of Biosimilar Contingent Value Rights, Payable Oct. 7 to Holders of Record Sept. 30 - marketscreener.com
Coherus Oncology Announces Special Dividend Of Biosimilar Contingent Value Rights - tradingview.com
Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights - GlobeNewswire
Coherus will give eligible holders rights to cash from former assets—but they may expire unpaid - Stock Titan
Coherus Oncology, Inc., Coherus Intermediate Corp, Surface Oncology, LLC, and InteKrin Therapeutics Inc., Enter into Loan and Security Agreement - marketscreener.com
Q3 EPS Estimates for Coherus Oncology Cut by HC Wainwright - MarketBeat
Coherus Oncology (CHRS) Q2 2026 Earnings Call Transcript - The Globe and Mail
ETFs Investing in Coherus Oncology, Inc. Stocks - TradingView
CHRS Maintained by Guggenheim -- Price Target Lowered to $10.00 - GuruFocus
Coherus Oncology Is Maintained at Buy by Guggenheim - Moomoo
Earnings call transcript: Coherus Oncology posts Q2 2026 EPS beat, shares fall - Investing.com Nigeria
H.C. Wainwright Maintains Coherus Oncology(CHRS.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Coherus Oncology, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Coherus Oncology (CHRS) Drops 7.24% to $1.34, Pressing Key Support at $1.27Synthetic Long - vinanet.vn
Coherus Oncology Inc (CHRS) (Q2 2026) Earnings Call Highlights: - GuruFocus
Coherus Oncology Inc (CHRS) (Q2 2026) Earnings Call Highlights: LOQTORZI Growth and Pipeline ... - finance.yahoo.com
Coherus Oncology, Inc. 2026 Q2 10-Q Highlights: Financials, Risks, and Forward-Looking Statements for Investors - Minichart
Coherus Oncology Q2 2026 Results: LOQTORZI Revenue Growth, Pipeline Progress, and Financial Update - Minichart
CHRS Looks 83.5% Overvalued on GF Value™ - GuruFocus
Coherus Oncology Q2 Earnings Call Highlights - MarketBeat
Coherus Oncology : Reports Second Quarter 2026 Financial Results and Provides Business Update - marketscreener.com
Coherus Oncology (NASDAQ:CHRS) Announces Quarterly Earnings Results - MarketBeat
CHRS: LOQTORZI sales rose 15% in Q2, with key clinical data readouts expected later in 2026 - TradingView
Coherus Oncology Inc reports results for the quarter ended June 30Earnings Summary - tradingview.com
Is Coherus Oncology Inc (CHRS) Worth the Investment After Q2 Ear - GuruFocus
Coherus Oncology (CHRS) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Coherus Oncology (NASDAQ: CHRS) posts Q2 2026 loss amid growing LOQTORZI revenue - Stock Titan
Coherus Oncology: Q2 Earnings Snapshot - Barchart.com
Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Coherus Oncology Q2 revenue rises 40% on higher LOQTORZI volume, but slightly falls below estimates - TradingView
Coherus Oncology Q2 Revenue Rises To $14.3 Million - quiverquant.com
CHRS: Q2 2026 revenue up 39% year-over-year, net loss narrows, and pipeline advances continue - TradingView
BRIEF-Coherus Oncology Q2 Net Income USD -20.631 Million - TradingView
Coherus projects October data disclosure as cancer trials mature - Stock Titan
CHRS Q2'26 Earnings: EPS estimate is (0.24) USD - TradingView
Coherus Oncology Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
CHRS Q1 2026 Earnings: Loss Narrower Than Expected, Yet Shares Shed 4.08%Earnings Miss Streak - vinanet.vn
CHRS Q1 2026 Earnings: Loss Narrows More Than Expected, Shares Slip 4.08%Earnings Call Transcript - vinanet.vn
Coherus Oncology: The Catalyst Rich Period Is Here (NASDAQ:CHRS) - Seeking Alpha
Lobbying Update: $95,000 of COHERUS BIOSCIENCES INC. lobbying was just disclosed | CHRS Stock News - Quiver Quantitative
BlackRock (CHRS holder) discloses 8.93M Coherus Oncology shares under sole control - Stock Titan
CHRS|Coherus BioSciences Inc|Price:1.410|Chg%:-0.050 - TradingKey
Coherus Oncology Market Sentiment - Benzinga España
CHRS|Coherus BioSciences Inc|Price:1.410|Chg%:-0.020 - TradingKey
Coherus BioSciences stock trades lower as revenue pressure and patent loss reshape outlook - Ad-hoc-news.de
CHRS Q2'26 Earnings: revenue estimate is 14.41M USD - TradingView
Coherus Oncology to report Q2 2026 financial results on August 5 - scanx.trade
Coherus BioSciences stock trades around recent lows as revenue declines and oncology pivot continues - Ad-hoc-news.de
Coherus Oncology Announces Date for Second Quarter 2026 Financial Results Conference Call and Webcast - Quiver Quantitative
Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026 - The Manila Times
Coherus to webcast second-quarter results Aug. 5 at 5 p.m. - Stock Titan
Q3 2025 Coherus Oncology Inc Earnings Call Transcript - GuruFocus
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):